This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...

Fiscal fourth-quarter revenue at Costco misses analysts’ estimates, Bristol Myers surges after the FDA approves an oral ...

Shares jumped 6% in premarket trading after the Food and Drug Administration approved a treatment for [schizophrenia patients]( ...

The US FDA has approved Bristol Myers Squibb’s oral medicine, Cobenfy, for treating schizophrenia in adults. This is the ...

Stock futures dipped early Friday morning as investors geared up to closely monitor new personal spending and inflation data. These economic indicators could of ...

Cobenfy is the first FDA-approved antipsychotic that targets cholinergic receptors instead of dopamine receptors.

The vice president on Thursday pledged to continue support to Ukraine as she and the Ukrainian president discussed his ...